Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Myelodysplastic Syndrome

St. Jude Children's Research Hospitalprotein_peptidePhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
73/ 100

Competitive context

314 Active assets in the Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Fludarabine
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB

View all 50 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →